Isogenic experiments showed that LY9 KO in CD4+ αβ T lymphocytes and HuT78 T-lymphoma cells impaired the upregulation of T-bet and RORγT induced by polyclonal stimuli or coculture with Raji B lymphoma cells (with or without LY9 KO) plus blinatumomab (Fig. 5H, S16A–D). Here, LY9 is linked to lymphoma.